Viewing Study NCT02815033

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:00 AM
Ignite Modification Date: 2026-03-02 @ 4:04 PM
Study NCT ID: NCT02815033
Status: COMPLETED
Last Update Posted: 2022-04-14
First Post: 2016-06-18
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
Sponsor: The European Uro-Oncology Group
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Prostate Cancer Metastatic View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Hormono-Sensitive prostate cancer View
None Enzalutamide View
None Imaging View
None PET/CT View
None Whole body MRI View
None Circulating tumour cells View
None Cell-free tumour DNA View